drugset / Trial / NCT03766867

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

NCT03766867

Phase 2 Completed 80 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days

Timeline

Start
2018-12-03
Primary completion
2019-07-31
Completion
2019-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg Intravenous
Subject Vortioxetine Unknown 25 mg Intravenous